Key Developments: Cyberonics Inc (CYBX.OQ)

CYBX.OQ on NASDAQ Stock Exchange Global Select Market

56.80USD
22 Aug 2014
Price Change (% chg)

$-1.47 (-2.52%)
Prev Close
$58.27
Open
$56.87
Day's High
$57.98
Day's Low
$56.65
Volume
128,449
Avg. Vol
84,812
52-wk High
$73.48
52-wk Low
$49.69

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cyberonics Inc reaffirms FY 2015 outlook
Thursday, 21 Aug 2014 07:00am EDT 

Cyberonics Inc:Reaffirmed FY 2015 guidance.Expects FY 2015 net sales to be in the range of $300 - $307 mln.Expects FY 2015 adjusted net income to be in the range of $62 - $64 mln.Expects FY 2015 adjusted diluted earnings per share (EPS) will be in the range of $2.33 to $2.39.FY 2015 revenue of $304 mln, net income of $63 mln, EPS of $2.36 - Thomson Reuters I/B/E/S.  Full Article

Cyberonics gives FY 2015 guidance; revenue guidance below analysts' estimates
Wednesday, 4 Jun 2014 07:00am EDT 

Cyberonics Inc:Expects FY 2015 net sales to be in the range of $300 to $307 mln.Expects FY 2015 Income from operations to be in the range of $96 to $99 mln.Expects FY 2015 net income to be in the range of $62 to $64 mln.Expects FY 2015 diluted earnings per share (EPS) will be in the range of $2.33 to $2.39.FY 2015 revenue of $315 mln, net income of $64 mln and EPS of $2.38 - Thomson Reuters I/B/E/S.  Full Article

Cyberonics Inc announces CE Mark approval of AspireSR generator for VNS therapy
Thursday, 20 Feb 2014 07:15am EST 

Cyberonics Inc:Says the CE Mark (ConformitĂ© EuropĂ©enne) approval in Europe for the AspireSR generator, the sixth-generation VNS Therapy generator.Says AspireSR generator provides the well-established benefits of VNS Therapy, coupled with a new feature - Automatic Stimulation in response to detection of a seizure.Says proprietary technology enables the AspireSR generator to analyze relative heart rate changes to detect and respond to seizures.Says this technology is based on a growing body of evidence that seizures are often accompanied by an increase in heart rate (ictal tachycardia).Says with the Automatic Stimulation feature, the AspireSR generator better aligns stimulation with the clinical onset of a seizure.  Full Article

Cyberonics Inc reaffirms FY 2014 revenue and income from operations guidance; increases FY 2014 net income and EPS guidance
Thursday, 20 Feb 2014 07:00am EST 

Cyberonics Inc:Maintains fiscal 2014 net sales guidance to be in the range of $281 million to $285 million.Maintains fiscal 2014 adjusted non-GAAP income from operations to be in the range of $86 million to $88 million.Increases fiscal 2014 adjusted non-GAAP net income to be in the range from $55 million to $57 million.Increases fiscal 2014 adjusted non-GAAP diluted earnings per share (EPS) to be in the range from $2.00 to $2.05.Guidance for income from operations, net income and diluted earnings per share (EPS) was adjusted by $7.4 million, $4.8 million (net of tax) and $0.17 cents per share, respectively, for the litigation settlement recorded in the first quarter of fiscal 2014.Fiscal 2014 revenue of $284 million, net income of $55 million and EPS of $2.02 - Thomson Reuters I/B/E/S.  Full Article

Cyberonics Inc reaffirms FY 2014 guidance - Conference Call
Wednesday, 15 Jan 2014 06:00pm EST 

Cyberonics Inc:Sees FY 2014 revenue guidance at $281 million to $285 million.Sees FY 2014 the operating income at $86 million to $88 million.Sees FY 2014 adjusted net income guidance of $54 million to $56 million.Sees FY 2014 adjusted earnings per share of $1.97 to $2.03.FY 2014 EPS of $2.02, revenue of $284 million, EBIT of $87 million and net income of $55 million - Thomson Reuters I/B/E/S Estimates.  Full Article

Cyberonics Inc announces results from E-36 study of VNS Therapy delivered by The AspireSR Generator
Sunday, 8 Dec 2013 11:00am EST 

Cyberonics Inc:Says that results from the E-36 clinical study of the AspireSR generator were presented at the annual AES Meeting.Says that Paul Boon and clinical research colleagues at 13 other European centers implanted a total of 31 patients with the investigational AspireSR generator, which provides "normal mode" VNS Therapy augmented by seizure response stimulation.Says that after the implant procedure and initial stimulation adjustment period, patients were admitted to an epilepsy monitoring unit for up to five days and monitored to identify seizures and collect heart-rate data.Says that the study met its primary endpoint in that the AspireSR generator, with IntelliSense cardiac-based seizure detection, detected more than 80% of seizures accompanied by ictal tachycardia (heart-rate increase) at a range of programmable settings.Says the potential false detection rates were low.  Full Article

Cyberonics Inc announces expansion of share repurchase program
Thursday, 5 Dec 2013 07:42am EST 

Cyberonics Inc:Says the board has approved a new share repurchase program of one million shares.This new authorization is expected to commence shortly and is expected to be completed by the end of fiscal 2015.  Full Article

Cyberonics Inc Raises FY 2014 Revenue And EPS Guidance; Raises Low End Of Prior FY 2014 EBIT And Net Income Guidance To A Range In Line with Analysts' Estimates
Thursday, 21 Nov 2013 07:00am EST 

Cyberonics Inc announced that for fiscal 2014, it expects net sales to be in the range of $281 million to $285 million as compared to previous guidance of $279 million to $283 million, adjusted non-GAAP income from operations to be in the range of $86 million to $88 million as compared to previous guidance of $85 million to $88 million, Adjusted non-GAAP net income in the range from $54 million to $56 million as compared to previous guidance of $53 million to $56 million and adjusted non-GAAP diluted earnings per share (EPS) will be in the range from $1.97 to $2.03 as compared to previous guidance of $1.93 to $2.01. Guidance for income from operations, net income and diluted earnings per share (EPS) was adjusted by $7.4 million, $4.8 million (net of tax) and $0.17 cents per share respectively, for the litigation settlement recorded in the first quarter of fiscal 2014. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $282 million, EBIT of $86 million, net income of $55 million and EPS of $1.98 for fiscal 2014.  Full Article

Cyberonics Inc Reaffirms FY 2014 Guidance
Thursday, 22 Aug 2013 07:01am EDT 

Cyberonics Inc is re-affirming for fiscal 2014 guidance, Net sales are expected to be in the range of $279 million to $283 million; Adjusted non-GAAP income from operations is expected to be in the range of $85 million to $88 million; Adjusted non-GAAP net income for fiscal 2014 is expected to be in the range from $53 million to $56 million; Adjusted non-GAAP income per diluted share (EPS) will be in the range from $1.93 to $2.01. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $281 million, EBIT of $85 million, net income of $54 million and EPS of $1.98 for fiscal 2014.  Full Article

Cyberonics Inc Issues FY 2014 Guidance; Revenue And EPS Guidance Above Analysts' Estimates
Wednesday, 5 Jun 2013 07:00am EDT 

Cyberonics Inc announced that for fiscal 2014, it expects net sales to be in the range of $279 million to $283 million, income from operations to be in the range of $85 million to $88 million, net income to be in the range from $53 million to $56 million and diluted earnings per share (EPS) to be in the range from $1.93 to $2.01. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $277 million, EBIT of $85 million, net income of $53 million and EPS of $1.91 for fiscal 2014.  Full Article

Search Stocks